Back to results
US 2021/0275557 A1Published application
Modified aminoglycoside compounds and uses thereof in disabling bacterial ribosome
AssigneeTechnion Research & Development Foundation Limited
InventorsTimor BAASOV, Boris SMOLKIN, Alina KHONONOV, Michal SHAVIT KISHKOBER, Valery BELAKHOV
Life of this patent
Estimating the term…
Abstract
Modified aminoglycoside compounds represented by Formula I as defined and described in the specification are provided. The modified aminoglycosides feature a diamine-containing functional moiety at one or more of positions 3′, 4′ and 6′. Uses of the modified aminoglycosides as antimicrobial (e.g., antibacterial) agents, and in treating medical conditions associated with microorganisms, are also provided.
Claims20
A compound represented by Formula I:
- or a pharmaceutically acceptable salt thereof,
- wherein:
- the dashed line indicates a stereo-configuration of position 6′ being an R configuration or an S configuration;
- X1 is O or S;
- Rx1, Rx2, Ry1 and Rz are each independently selected from hydrogen, alkyl and cycloalkyl;
- Ry2-Ry9 and Rw1-Rw3 are each independently selected from hydrogen, alkyl, and cycloalkyl;
- R1, R3 and R4 are each independently NR23R24, OR20 or a diamine-containing moiety, wherein R20 is hydrogen, alkyl, cycloalkyl or the diamine-containing moiety, and each of R23 and R24 is independently hydrogen, alkyl, cycloalkyl or acyl, provided that at least one of R1, R3 and R4 is or comprises the diamine-containing moiety;
- R5 and R6 are each independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heteroalicyclic, aryl, heteroaryl and OR16, wherein Rib is independently selected from hydrogen, a monosaccharide moiety and an oligosaccharide moiety;
- and
- R7-R9 are each independently selected from the group consisting of hydrogen and acyl,
- wherein said diamine-containing moiety comprises at least two amine-containing groups and at least one linking group linking said at least two amine-containing groups, and wherein said amine-containing groups and said at least one linking group are arranged such that:
- (i) a difference in the pKa of at least two of said amine-containing groups is at least 1;
- and/or
- (ii) when the compound is in a physiological environment, at least one of said amine-containing groups is protonated at physiological pH while at least another of said amine-containing groups is non-protonated;
- and/or
- (iii) when the compound interacts with a prokaryotic ribosomal RNA decoding site (A-site), the RNA undergoes a conformational change such that an O—P—O angle of at least one phosphodiester bond is higher than 100°;
- and/or
- (iv) when the compound interacts with a prokaryotic ribosomal RNA decoding site (A-site), the functional moiety is capable of adopting a configuration in which one of said amine-containing groups is in close proximity and suitable orientation so as to interact with a 2′-OH group of a ribose of a nucleotide in said RNA and another amine-containing moiety is in close proximity and suitable orientation so as to interact with a phosphate group of a nucleotide of an adjacent nucleotide.
15 more elements
Dependencies are inferred from the claim text.